David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATVI
Activision Blizzard
ATVI
|
+$757M |
| 2 |
Alibaba
BABA
|
+$544M |
| 3 |
Booking.com
BKNG
|
+$475M |
| 4 |
XLNX
Xilinx Inc
XLNX
|
+$377M |
| 5 |
Caterpillar
CAT
|
+$285M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.07B |
| 2 |
Amazon
AMZN
|
+$486M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$443M |
| 4 |
Salesforce
CRM
|
+$363M |
| 5 |
Qualcomm
QCOM
|
+$352M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.87% |
| 2 | Consumer Discretionary | 9.92% |
| 3 | Healthcare | 7.34% |
| 4 | Financials | 7.06% |
| 5 | Communication Services | 6.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4151
Southside Bancshares
SBSI
$951M
| $333K | ﹤0.01% |
+8,691
| New | +$320K |
|
4152
Atlanta Braves Holdings Series A
BATRA
$3.71B
| $331K | ﹤0.01% |
12,313
-9,395
| -43% | -$251K |
|
4153
Minerva Neurosciences
NERV
$245M
| $331K | ﹤0.01% |
23,757
-15,950
| -40% | -$240K |
|
4154
Omega Flex
OFLX
$272M
| $331K | ﹤0.01% |
2,319
| – | – |
|
|
ZENV
4155
DELISTED
Zenvia
ZENV
| $331K | ﹤0.01% |
+24,061
| New | +$345K |
|
4156
CEVA Inc
CEVA
$756M
| $330K | ﹤0.01% |
7,740
-3,836
| -33% | -$174K |
|
|
BFX
4157
DELISTED
BowFlex Inc.
BFX
| $327K | ﹤0.01% |
+35,171
| New | +$452K |
|
4158
CDW
CDW
$17.5B
| $326K | ﹤0.01% |
1,793
-5,730
| -76% | -$1.08M |
|
4159
Insteel Industries
IIIN
$586M
| $326K | ﹤0.01% |
8,571
-14,165
| -62% | -$522K |
|
|
SVM
4160
Silvercorp Metals
SVM
$2.82B
| $326K | ﹤0.01% |
+85,500
| New | +$387K |
|
|
AVDL
4161
DELISTED
Avadel Pharmaceuticals
AVDL
| $324K | ﹤0.01% |
33,041
+19,405
| +142% | +$153K |
|
4162
Jakks Pacific
JAKK
$292M
| $324K | ﹤0.01% |
+27,249
| New | +$344K |
|
4163
PUT
Nu Skin
NUS
$232M
| $324K | ﹤0.01% |
+8,000
| New | +$405K |
|
4164
PUT
Polaris
PII
$3.63B
| $323K | ﹤0.01% |
+2,700
| New | +$343K |
|
|
FSR
4165
CALL
DELISTED
Fisker Inc.
FSR
| $322K | ﹤0.01% |
+22,000
| New | +$331K |
|
|
GSQB
4166
DELISTED
G Squared Ascend II Inc.
GSQB
| $322K | ﹤0.01% |
+32,940
| New | +$321K |
|
4167
Pinnacle Financial Partners Inc
PNFP
$15.2B
| $321K | ﹤0.01% |
3,414
-4,556
| -57% | -$419K |
|
4168
Duluth Holdings
DLTH
$143M
| $320K | ﹤0.01% |
+23,493
| New | +$375K |
|
|
HES
4169
PUT
DELISTED
Hess
HES
| $320K | ﹤0.01% |
4,100
-1,000
| -20% | -$73.7K |
|
4170
Alpha Metallurgical Resources
AMR
$2.62B
| $319K | ﹤0.01% |
+6,400
| New | +$230K |
|
|
DADA
4171
DELISTED
Dada Nexus
DADA
| $319K | ﹤0.01% |
+15,917
| New | +$360K |
|
4172
PUT
8x8 Inc
EGHT
$280M
| $318K | ﹤0.01% |
13,600
| – | – |
|
4173
PUT
Repligen
RGEN
$10.3B
| $318K | ﹤0.01% |
+1,100
| New | +$282K |
|
4174
Root
ROOT
$891M
| $317K | ﹤0.01% |
3,344
-138
| -4% | -$17.1K |
|
4175
CALL
Criteo S.A.
CRTO
$841M
| $315K | ﹤0.01% |
8,600
-8,800
| -51% | -$339K |
|
Similar funds
David Shaw's Q3 2021 Portfolio in Review
As of Q3 2021, David Shaw held 5,618 positions worth $111B, down 4.4% from $116B the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.
David Shaw withdrew a net $8.92B in Q3 2021, closing 695 positions and reducing 1,634 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $228M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 16% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, David Shaw opened a new position in Sea Limited worth $206M.
- David Shaw's largest Q3 2021 buy was Sea Limited: 645,697 shares worth $206M.
- David Shaw added most to Activision Blizzard in Q3 2021, an estimated $757M increase.
- David Shaw's biggest Q3 2021 reduction was Apple, cutting an estimated $1.07B.
- David Shaw fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $228M.
- David Shaw's ten largest holdings make up 9.2% of its $111B portfolio in Q3 2021.
- David Shaw opened 915 new positions and closed 695 in Q3 2021.
- David Shaw's portfolio value fell 4.4% quarter-over-quarter to $111B.
Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.